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women. GBS transmission to the newborn is associated with
risk of pneumonia, septicemia, and meningitis (1–3). In the
United States and other developed countries, implementation
of universal antenatal GBS culture screening and administration of intrapartum antibiotic prophylaxis has reduced GBS
incidence in the first few days of life; however, it has not had a
similar impact on late-onset infections, which now represent
approximately one-third of total cases (4). Up to half of all
infants with late-onset GBS also develop meningitis, which carries a high incidence (⬎40%) of neurocognitive sequelae among
survivors (5). In a recent meta-analysis, the overall incidence of
GBS infection in infants ⬎3 months of age in the Americas and
Europe is ⬃0.53– 0.67 cases/1000 births, with an overall case
fatality rate of 7–10% (6). The emergence of antibiotic-resistant
GBS strains has become an increasing concern (1, 7, 8).
Human milk oligosaccharides (HMOs) are a group of complex carbohydrates that are highly abundant in human milk
(10 –15 g/liter) but not in infant formula (reviewed in Ref. 9).
HMOs are comprised of five monosaccharides: D-glucose (Glc),
D-galactose (Gal), GlcNAc, L-fucose, and sialic acid (N-acetylneuraminic acid). The Gal-Glc disaccharide (lactose) backbone
can be further elongated by up to 15 Gal-GlcNAc repeats and
can be sialylated or fucosylated. Over 150 structurally distinct HMOs have been identified, comprised of neutral (nonsialylated) and acidic (sialylated) forms, and the amount and
composition are highly variable between women (reviewed
in Ref. 10).
HMOs are not digested by the infant and reach the colon
intact, where they serve as metabolic substrates for specific,
potentially beneficial bacteria and help shape the infant microbiome. HMOs also act as soluble receptor decoys to prevent
attachment of microbial pathogens to the host (11–14). HMOs
are partially absorbed and reach the systemic circulation of the
tral human milk oligosaccharide; LNT, lacto-N-tetraose; LNnT, lacto-Nneotetraose; LNnH, lacto-N-neohexaose; LNFPI, lacto-N-fucopentaose I;
LNDFHII, lacto-N-difucohexaose II; LnNO, lacto-N-neooctaose; LNnDFH,
lacto-N-neodifucohexaose; LNnFPV, lacto-N-neofucopentaose; LNFPV,
lacto-N-fucopentaose V; THB, Todd-Hewitt broth; SF-RPMI 1640, serumfree RPMI 1640; ANOVA, analysis of variance.

J. Biol. Chem. (2017) 292(27) 11243–11249
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.

11243

Downloaded from http://www.jbc.org/ at Washington University on July 29, 2017

Streptococcus agalactiae (group B Streptococcus, GBS) is a
leading cause of invasive bacterial infections in newborns, typically acquired vertically during childbirth secondary to maternal vaginal colonization. Human milk oligosaccharides (HMOs)
have important nutritional and biological activities that guide
the development of the immune system of the infant and shape
the composition of normal gut microbiota. In this manner,
HMOs help protect against pathogen colonization and reduce
the risk of infection. In the course of our studies of HMO-microbial interactions, we unexpectedly uncovered a novel HMO
property to directly inhibit the growth of GBS independent of
host immunity. By separating different HMO fractions through
multidimensional chromatography, we found the bacteriostatic
activity to be confined to specific non-sialylated HMOs and synergistic with a number of conventional antibiotic agents. Phenotypic screening of a GBS transposon insertion library identified
a mutation within a GBS-specific gene encoding a putative glycosyltransferase that confers resistance to HMOs, suggesting
that HMOs may function as an alternative substrate to modify a
GBS component in a manner that impairs growth kinetics. Our
study uncovers a unique antibacterial role for HMOs against a
leading neonatal pathogen and expands the potential therapeutic utility of these versatile molecules.

Human milk oligosaccharides inhibit GBS growth

infant (15, 16) and appear intact in the urine of breast-fed
infants (17, 18), with the potential to exert effects in organs
other than the gut and including the urinary tract. Most intriguingly, HMOs also appear in the urine of pregnant women as
early as the end of the first trimester (19), suggesting that
HMOs might already affect pregnant women and the growing
fetus long before birth.
In a previous study, we demonstrated that HMOs regulate
the host innate immune response in bladder epithelial cells
to prevent invasion and cytotoxicity caused by uropathogenic
Escherichia coli (UPEC) without any direct interference with
bacterial growth (20). To delineate whether HMOs generate
similar effects with other neonatal pathogens, we examined
the effect of HMOs on GBS, which is commonly found in the
urogenital tract of pregnant women. Unexpectedly, we found
that HMOs directly inhibit the growth of GBS, a property not
shared with UPEC, Pseudomonas aeruginosa, or Staphylococcus aureus. Further investigation revealed a unique aspect
of HMOs that causes a significant GBS growth defect.

Results
Human milk oligosaccharides inhibit growth of group B
Streptococcus
To evaluate the potential antimicrobial effect(s) of HMO on
a group of bacterial pathogens, we resuspended ⬃105 cfu of
each bacterial overnight culture in serum-free tissue culture
medium (RPMI) with or without 2 mg/ml of HMOs isolated
from pooled human milk (pHMO) and then incubated for 4 h.
pHMOs did not affect the growth of UPEC, P. aeruginosa, and
methicillin-resistant S. aureus. However, growth of the GBS
test strain (serotype III isolate COH1) was reduced by ⬃10-fold
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(p ⬍ 0.05) (Fig. 1A). We confirmed that HMOs are bacteriostatic and not bactericidal because they did not kill GBS even at
very high concentration (Fig. 1B). pHMO impaired the growth
of the three most common GBS serotypes—serotypes III (strain
COH1), Ia (strain A909), and V (strain NCTC10/84)—in a
dose-dependent manner between 0.25–1.0 mg/ml (Fig. 1C).
The neutral fraction of HMOs possesses the GBS inhibitory
activity
Galacto-oligosaccharides (GOS) are sometimes used to supplement infant formula to mimic the prebiotic properties of
HMOs. However, GOS are structurally different from HMOs
and consist of linear chains of two to six galactose residues
linked to a single glucose. Unlike pHMOs, GOS did not impact
GBS growth (Fig. 2A). Moreover, pHMOs pretreated with proteinase K retained their GBS-inhibitory activity (supplemental
Fig. S1). Thus, pHMO-mediated inhibition of GBS growth is
neither a nonspecific effect of oligosaccharides nor does it
appear to require a protein.
Next, we separated pHMOs into sialylated, acidic HMOs
(aHMOs) and non-sialylated, neutral HMOs (nHMOs) (9).
Although nHMOs exerted a similar effect as pHMOs, aHMOs
did not inhibit GBS growth (Fig. 2B). Consistent with this
result, sialidase treatment of pHMOs to remove sialic acid moieties, which was confirmed by HPLC analysis, did not alter the
inhibitory properties (Fig. 2C). At 1.0 mg/ml, nHMOs slowed
serotype III GBS (COH1) growth by 98.2%, serotype Ia GBS
(A909) growth by 97.0%, and serotype V GBS (NCTC10/84)
growth by 96.0% (Fig. 2D). At a lower dose of 0.25 mg/ml,
nHMOs inhibited growth of the serotype III and Ia GBS strains

Downloaded from http://www.jbc.org/ at Washington University on July 29, 2017

Figure 1. Human milk oligosaccharides inhibit GBS growth. A, bacteria were cultured for 4 h in SF-RPMI in the absence (solid lines) or presence (dashed lines)
of pHMO in a 37 °C, 5% CO2 incubator. Pa, P. aeruginosa; MRSA, methicillin-resistant S. aureus; GAS, group A Streptococcus. B, GBS serotype III strain COH1 was
incubated with 1–10 mg/ml of pHMO in SF-RPMI. C, growth of three GBS strains of differing serotypes in the presence of pHMOs at the indicated concentrations. Relative growth represents cfu at the indicated point with respect to initial cfu inoculum ⫻ 100%. Solid line, no pHMOs; dotted line, with pHMOs; error bars,
S.E. (n ⫽ 3). *, p ⬍ 0.05, one-way ANOVA, Tukey’s multiple comparison’s test.

Human milk oligosaccharides inhibit GBS growth

by more than 40-fold (p ⬍ 0.01), an effect more potent than
pHMOs at the same dose (Fig. 1C).
Identification of neutral HMOs that inhibit GBS growth
To identify specific neutral oligosaccharide(s) responsible
for GBS-inhibitory activity, we separated nHMOs into 10 fractions via size exclusion chromatography. We evaluated the bacteriostatic activity of each fraction by monitoring the GBS
growth rate and found the strongest growth inhibition in the
fourth and sixth size fractions (Fig. 3A). Based on HPLC profiles, these fractions primarily contained HMOs with up to
eight monosaccharide moieties. Based on this lead, we selected
nine commercially available oligosaccharides, each with slight
modifications in the core structure known to exist in HMOs:
lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-Nneohexaose (LNnH), lacto-N-fucopentaose I (LNFPI), lacto-Ndifucohexaose II (LNDFHII), lacto-N-neooctaose (LnNO),
lacto-N-neodifucohexaose (LNnDFH), lacto-N-neofucopentaose (LNnFPV), and lacto-N-fucopentaose V (LNFPV). GBS
were challenged with 5 mg/ml of these individual oligosaccharides, and growth was observed to be significantly (60 –70%)
inhibited by LNT and its fucosylated derivative LNFPI (Fig. 3B).
Most intriguingly, the LNT structural isomer LNnT (Fig. 3C)
showed no significant inhibition of GBS growth.
Disruption of GBS glycosyltransferase leads to resistance
against HMOs
To identify bacterial factors involved in GBS susceptibility to
HMOs, we screened ⬃1200 serotype III GBS (COH1) transposon Tn917⌬E mutants from our previously published library
(21) for resistance to growth suppression by 2.5 mg/ml of

pHMOs. This screen selected for a candidate mutant that
exhibited normal growth over 7 h despite exposure to pHMOs
(Fig. 4A). Through chromosomal sequence analysis, we identified the transposon insertion in this mutant to lie in the promoter of a gene annotated as gbs0738. Based on the Basic Local
Alignment Search Tool (BLAST), gbs0738 encodes a putative
glycosyltransferase that belongs to the carbohydrate-active
enzymes (CAZY) GT-8 family and is conserved among 18
group B Streptococcus subspecies, with high levels of identity
(99%) in strains, including serotype Ia A909 and serotype V
NCTC10/84 (supplemental Fig. S2). To confirm that the transposon Tn917⌬E insertion was not accompanied by unlinked
mutations in the genome, we created a targeted in-frame insertion mutant in the wild-type strain COH1 to create knockout
strain ⌬0738. The targeted ⌬0738 mutant recapitulated the
growth profile of the original transposon mutant and was not
susceptible to the bacteriostatic effect of pHMO (p ⬎ 0.05) (Fig.
4, B and C). This finding confirms that the resistance to HMOs
is specifically linked to inactivation of the gbs0738 gene.
Of note, the GT-8 glycosyltransferase shares some sequence
homology with LPS glycosyltransferase RfaJ, an important
outer membrane biosynthesis protein in Gram-negative bacteria (22). Because GBS is a Gram-positive pathogen lacking an
outer membrane, we postulated this glycosyltransferase could
promiscuously catalyze the glycosylation of HMOs into polysaccharide components of the GBS capsule or incorporate
them into peptidoglycan/glycan-binding proteins (i.e. lectins)
in the GBS cell wall. To explore this hypothesis, we first monitored the growth kinetics of a GBS serotype III capsule-deficient mutant (strain HY106 (23)) in the presence of HMOs. We
J. Biol. Chem. (2017) 292(27) 11243–11249
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Figure 2. The neutral fraction of human milk oligosaccharides exerts a bacteriostatic effect on GBS. A, GBS serotype III strain COH1 growth curve in the
presence of 5 mg/ml of pooled HMOs or GOS in SF-RPMI medium. B, GBS growth in SF-RPMI supplemented with pHMO, nHMO, or aHMO. C, GBS growth in
untreated pooled HMO (open circles) or sialidase-treated pooled HMO (closed circles). D, GBS strain COH1, A909, and NCTC growth in the presence of neutral
HMO fractions at the indicated concentrations. Relative growth represents cfu at the indicated point with respect to initial cfu inoculum ⫻ 100%. Error bars, S.E.
(n ⫽ 3). ***, p ⬍ 0.001; **, p ⬍ 0.01; *, p ⬍ 0.05; ns, not significant; one-way ANOVA, Tukey’s multiple comparison’s test or Dunnett’s post-test.

Human milk oligosaccharides inhibit GBS growth

Figure 4. A GBS glycosyltransferase mutant is not susceptible to HMO-mediated killing. A, transposon library screening identified a mutant GBS that is
resistant to HMO treatment. 100 l of GBS COH-1 (A600 ⫽ 0.01) is grown in SF-RPMI supplemented with 5 mg/ml of pHMO for 24 h at 37 °C. A600 was measured
at 30-min intervals over 8 h through a Bioscreen C MBR system. Tn, transposon. B, growth curves of GBS COH1 WT (black) or ⌬0738 targeted knockout (red) in
serum-free RPMI media (solid lines) or with 5 mg/ml pHMO (dotted line) over 8 h at 37 °C. C, relative GBS growth after 4 h of incubation in SF-RPMI with or without
5 mg/ml of pHMO. D, growth curves of GBS COH1 WT (black), HY106 (red) and ⌬iagA (blue) in SF-RPMI (solid lines) or with 5 mg/ml of neutral HMO (dotted lines).
Relative growth represents cfu at the indicated point with respect to initial cfu inoculum ⫻ 100%. ***, p ⬍ 0.001; ns, not significant.

found that the capsule-deficient mutant still exhibited significant growth inhibition in the presence of nHMO (Fig. 4D), suggesting that the capsule is not targeted by nHMOs. To delineate
whether GBS sensitivity to HMOs extends to the activity of
other glycosyltransferases, we studied a GBS mutant (⌬iagA)
encoding a group 1 glycosyltransferase (21) that likewise
remained sensitive to nHMO-mediated inhibition (Fig. 4D).
Thus, our results suggest that GBS susceptibility to nHMOs
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is attributed with some specificity to the gbs0738-encoded
glycosyltransferase.
Synergistic activity of HMOs and antibiotics against GBS
In serious or difficult-to-treat infections, combination antibiotic therapy is often considered to exploit synergistic activities and to reduce the risk of generating antimicrobial resistance. We examined whether prior exposure to HMOs could
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Figure 3. Identification of neutral HMO fraction(s) that block GBS growth. A and B, nHMOs were separated by size exclusion chromatography. A, a total of
10 fractions were isolated from 40 mg/ml neutral HMO. Relative growth of GBS within 2 h in each fraction (N1-N10 and RPMI as a control) is shown as A600 nm
4 h/2 h, which represents the ratio of optical density measured at 4 h divided by the optical density measured at 2 h. B, relative GBS growth (cfu recovered with
respect to initial inoculum) after 2 h of incubation in SF-RPMI alone (red columns) or supplemented with 5 mg/ml of individual commercially acquired neutral
oligosaccharides (black columns). Relative growth represents cfu at indicated point with respect to initial cfu inoculum ⫻ 100%. *, p ⬍ 0.01; **, p ⬍ 0.01; ***, p ⬍
0.001; one-way ANOVA, Tukey’s post-test. C, structures of LNT, LNnT, and LNFPI. Blue circles, glucose; yellow circles, galactose; blue squares, N-acetyl-glucosamine; red triangle, fucose.

Human milk oligosaccharides inhibit GBS growth

sensitize GBS to different pharmaceutical antibiotics. GBS
growth was monitored over 4 h at different concentrations of
nHMOs, and the IC50 was determined to be 0.899 mg/ml (Fig.
5A). We then measured the IC50 of GBS in the presence or
absence of 0.25 mg/ml, a sub-IC50 of nHMOs, in the presence of
the glycopeptide antibiotic vancomycin, the fluoroquinolone
antibiotic ciprofloxacin, or the ␤-lactam antibiotic imipenem.
The presence of nHMOs at a sub-IC50 concentration dramatically reduced the IC50 of both vancomycin (0.25 g/ml alone
versus 0.00602 g/ml with nHMOs) and ciprofloxacin (1.37
g/ml alone versus 0.0021 g/ml with nHMOs) (Fig. 5, B and C)
but did not improve the activity of imipenem (supplemental
Fig. S3). Calculation of the interaction index (Fig. 5D) revealed
the interaction between nHMO and vancomycin or ciprofloxacin to represent true synergism (I ⬍ 0.5).

Discussion
A growing body of evidence has documented a variety of
protective properties of HMOs against infectious agents. In
additiontomodulatinghostimmuneresponses(24,25),oligosaccharides can pose as receptor decoys to prevent adhesion of
microbial pathogens to epithelial surfaces (11–14). In a prior
study, we demonstrated that HMOs, specifically the sialylated
fraction of HMOs, and 3⬘-sialyllactose (3⬘SL) alone, support
host innate defense and reduce invasion of UPEC into bladder
epithelial cells. Conversely, in this study we found that certain
neutral, non-sialylated forms of HMOs may cause a significant
defect in GBS growth. To our knowledge, this is the first study
to associate HMOs with a direct antimicrobial effect. Among
the four bacterial species tested, the bacteriostatic effect of
HMOs was unique to GBS.

Through a combination of mutation and bioinformatics
analysis, we identified a conserved putative glycosyltransferase
family 8 member (gbs0738) that is required for GBS sensitivity
to HMOs. The predicted protein product of this GBS glycosyltransferase does not possess strong identity or similarity to
genes from other bacterial species, which may explain why
HMO inhibition is specific to GBS and not to other tested
organisms (Fig. 1A). This particular family of glycosyltransferases is characterized by the GT-A fold and DXD motif. The
GBS enzyme (gbs0738) shares high identity with an E. coli
enzyme within this family of glycosyltransferases that is
involved in synthesis of the outer core region of lipo-oligosaccharide, catalyzing the ␣-1,2 linkage of donor sugar to their
acceptors (26). In Streptococcus spp., glycosyltransferases participate in the biosynthesis of capsular polysaccharides, cell wall
peptidoglycan, and anchoring of lipotechoic acid within the cell
wall (27, 28). In GBS, glycosyltransferase-encoding cpsE is
important for the synthesis of the surface polysaccharide capsules (29), and iagA is a glycosyltransferase that aids in the
anchoring of lipotechoic acid (21), but neither are essential for
GBS growth (21, 29). GBS mutants lacking capsule or IagA,
however, remain sensitive to HMOs. Our results suggest that
growth inhibition by HMOs may depend on gbs0738-encoded
glycosyltransferase to catalyze incorporation of HMO components into the cell wall. Ongoing work aims to biochemically
characterize this glycosyltransferase and identify specific HMO
substrates and GBS targets.
LNT causes the highest inhibition of GBS growth (Fig. 3B).
LNT is one of the most abundant core structures in human milk
(0.5–1.5 g/liter in mature human milk) (30). Further, LNT has
J. Biol. Chem. (2017) 292(27) 11243–11249
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Figure 5. Neutral HMOs increase GBS sensitivity to antibiotics. A, IC50 curve of nHMOs. Cfu were recovered after 4 h of nHMO treatment at different
concentrations. B and C, IC50 curves of vancomycin (B) and viprofloxacin (C) in the presence (red) or absence (black) of 0.25 mg/ml of nHMOs that show GBS
growth inhibition. Error bars, S.E. (n ⫽ 3). D, the interaction index calculation formula.

Human milk oligosaccharides inhibit GBS growth

Experimental procedures
Bacterial strains, cells, media, and growth conditions
The wild-type GBS strain COH1 (serotype I and I) and its
mutant derivatives HY106 and ⌬iagA (21), A909 (serotype Ia),
NCTC10/84 (serotype V), and methicillin-resistant S. aureus
strain TCH1516 were grown overnight in Todd-Hewitt agar or
Todd-Hewitt broth (THB). P. aeruginosa strain PA14 and
UPEC strain CFT073 (O6:K2:H1, ATCC 700928) were grown
overnight in Luria-Bertani agar or broth. All bacteria were
propagated in standing culture to stationary phase at 37 °C in
5% CO2 unless stated otherwise.
Human milk oligosaccharide isolations
pHMOs were prepared as described previously (31) and
lyophilized for long-term storage. Milk from 36 different
donors was pooled to account for heterogeneity in HMO composition between different women. The human milk donation
program has been reviewed by the Institutional Review Board
(IRB) Chair at University of California, San Diego and certified
as exempt from IRB review under 45 CFR 46.101(b), category 4
because subjects cannot be identified and linked to generated
data. Pooled HMOs were separated into aHMO and nHMO by
anion exchange chromatography as described previously (31).
nHMOs were further separated by size using size exclusion
chromatography. pHMOs were disialylated by incubation with
neuraminidase from Vibrio cholerae. HMO composition was
analyzed by high-performance liquid chromatography and
mass spectrometry.
Sources of galacto-oligosaccharides and purified glycans
Galacto-oligosaccharides were generously provided by Friesland Campina Domo (the Netherlands). Purified glycans were
purchased from ELICITYL OligoTech威, which includes LNT,
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LNnT, LNnH, LNFPI, LNDFHII, LnNO, LNnDFH, LNnFPV,
and LNFPV.
GBS growth and susceptibility test
Overnight GBS growth was back-diluted to A600 ⫽ 0.01 in
serum-free RPMI 1640 (SF-RPMI) (Life Technologies) or supplemented with pooled or fractions of HMOs. To measure
growth, bacteria were grown in 100 l of medium at 37 °C. At
600 nm, absorbance was recorded at 30-min interval using the
BioScreen instrument (Growth Curves USA). To detect growth
in cfu, bacteria were grown in 100 l of medium at 37 °C in
humidified air with 5% CO2 over 2 or 4 h. Recombinant proteinase K (Roche) was used at 0.1 mg/ml.
GBS COH-1 transposon library
The transposon library was constructed as described previously (21). To screen for mutants resistant to HMOs, we normalized overnight cultures of transposon mutants to A600 of
0.1. Approximately 10 l of each mutant was cultured in 100 l
of SF-RPMI supplemented with 5 mg/ml of pooled HMOs.
Growth was monitored over an 8-h period at 37 °C by measuring optical density at 600 nm at a 30-min interval using a Bioscreen C MBR system.
GBS COH-1 ⌬0738 construct
To generate a targeted knockout, we cloned the gbs0738
gene to the temperature-sensitive vector PHY304. Briefly,
gbs0738 was PCR-amplified with primers XhoI-gbs0738F (5⬘CGATCTCGAGTGCTCAGGCACCTACAACTG-3⬘) ⫹ HindIII-gbs0738R (5⬘-CAGTAAGCTTAGCAGGCAAGTTCATCAAGAG-3⬘) to generate a 300-bp amplicon. The purified
PCR amplicon was digested with XhoI and HindIII and ligated
into previously digested pHY304. The construct was cloned
into E. coli DH5␣ and isolated by mini-prep. Approximately 1
g of PHY304-gbs0738 DNA was transformed into electrocompetent GBS at 1550 V. The transformed bacteria were
allowed to recover in 500 l of THB with 0.25 M sucrose at 30 °C
for 2 h while shaking at 220 RPM. Bacteria were grown overnight on Todd-Hewitt agar ⫹ 2 g/ml erythromycin at 30 °C.
After 2–3 days, colonies were selected and inoculated into 5 ml
of THB ⫹ 5 g/ml erythromycin at 30 °C overnight. The next
day, cultures were prepared in duplicate in THB ⫹ erythromycin at 30 °C and 37 °C to select for bacteria with the targeting
vector incorporated into the chromosome. Resultant single colonies from the 37 °C culture were isolated and confirmed for
single crossover mutation by PCR using primers M13F (5⬘GTTTTCCCAGTCACGAC-3⬘) and gbs0738R2 (5⬘-ACACGCTCCTCCTTTGATATT-3⬘). Wild-type GBS had an expected 1.67 kb PCR product, whereas the mutant had an
expected 6.5-kbp PCR product.
Statistical analysis
All experiments were performed in triplicate or quadruplicate and repeated in at least two independent experiments.
Error bars represent S.E. (n ⬎ 3) from multiple independent
experiments. Statistical analysis was performed using Student’s
unpaired two-tailed t test or one-way ANOVA for multiple
comparisons (GraphPad Prism version 5.03). *, p ⬍ 0.05; **, p ⬍
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been identified to block Entamoeba histolytica binding to epithelial cell surfaces (12). However, LNT has never been proposed to serve any direct antimicrobial function. One intriguing observation is that a slight conformational change of the
single 3GlcNAc␤1 residue of LNT to 4GlcNAc␤1 in LNnT
nearly abrogates its bacteriostatic effect on GBS (Fig. 3B). Our
results suggest that there is a strict 3GlcNAC␤1 conformation
requirement for maximal GBS inhibition.
HMOs have been found in the plasma (15, 16) and urine (17,
18) of breast-fed infants. Also, HMOs appear in the urine of
pregnant women as early as the end of first trimester. Although
the exact concentration of HMOs present in these areas is still
uncertain, our results support the notion that lower incidences
of GBS infections in breast-fed infants and already in pregnant
women could include a contribution from the antibacterial
properties of HMOs. Further, our demonstration of HMO synergism with certain pharmaceutical antibiotics suggests their
potential utility in adjunctive therapy of GBS infection. Future
animal studies as well as human cohort studies on human
mother-infant dyads may help identify associations of individual HMOs like LNT with GBS infection risk. It is intriguing to
envision the rational development of novel anti-infective strategies based on the natural template of human milk.
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0.01; and ***, p ⬍ 0.001 represent statistical significance. p ⬎
0.05 represents non-significance. IC50 was calculated using
non-linear regression curve fit using the equation log (inhibitor) versus response-variable slope. Error bars represent S.E.
(n ⫽ 3).
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